NAV
$35.90
AUM
$1.1B
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +10.35% | +3.54% | +8.85% | +24.22% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | HSBA.L | HSBC Holdings PLC | 1.97% |
| 2 | 6981.T | Murata Manufacturing Co Ltd | 1.52% |
| 3 | ASML.AS | ASML Holding NV | 1.27% |
| 4 | INGA.AS | ING Groep NV | 1.16% |
| 5 | GSK.L | GSK PLC | 1.16% |
| 6 | NOVN.SW | Novartis AG Registered Shares | 1.12% |
| 7 | BARC.L | Barclays PLC | 0.97% |
| 8 | STAN.L | Standard Chartered PLC | 0.97% |
| 9 | AZN.L | AstraZeneca PLC | 0.96% |
| 10 | CFR.SW | Compagnie Financiere Richemont SA Class A | 0.91% |
Under normal circumstances, the fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities. The fund will invest primarily in equity securities of issuers of all capitalization ranges that are located in at least three countries other than the U.S. It is expected that at least 40% of the fund's assets will be invested outside the U.S.
Inception Date: 2024-10-08